{"id":11259,"date":"2024-11-25T00:00:00","date_gmt":"2024-11-25T04:00:00","guid":{"rendered":"https:\/\/livingstagenew.wpenginepowered.com\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/"},"modified":"2026-06-25T09:00:45","modified_gmt":"2026-06-25T13:00:45","slug":"niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh","status":"publish","type":"transaction","link":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","title":{"rendered":"Niterra Ventures Company investe $18m in neoplas med GmbH"},"content":{"rendered":"\n

Il team Healthcare di Livingstone a D\u00fcsseldorf ha continuato il proprio ruolo di consulente per <\/strong>neoplas med GmbH<\/strong><\/a> nel suo terzo round di finanziamento. Il pioniere della tecnologia medica con sede a Greifswald sta rafforzando la sua collaborazione strategica con <\/strong>Niterra Ventures Company<\/strong><\/a> attraverso un aumento di capitale di $18m, finalizzato all’espansione del mercato per i suoi innovativi prodotti per la cura delle ferite. Con un investimento totale di $25m, Niterra Ventures Company aveva gi\u00e0 investito in neoplas med nel 2022 e nel 2023.<\/strong><\/p>

neoplas med, spin-off dell’Istituto Leibniz per la Scienza e la Tecnologia del Plasma (INP), ha sviluppato il getto di plasma freddo all\u2019argon kINPen\u00ae MED, un innovativo “plasma pen” che applica un getto di plasma preciso sulle ferite, accelerandone significativamente la guarigione. Studi clinici dimostrano che il tempo di trattamento pu\u00f2 essere ridotto del 50% rispetto ai metodi convenzionali, senza effetti collaterali o sviluppo di resistenze. neoplas med \u00e8 tra le pochissime aziende che utilizzano l\u2019argon come gas inerte per questa terapia quasi indolore e rapida, adatta al trattamento di ferite infette e croniche. Inoltre, con il suo “plasma pen”, neoplas med \u00e8 l\u2019unico produttore in Europa certificato secondo il Regolamento europeo sui dispositivi medici (MDR) per i prodotti a plasma freddo.<\/p>

“L\u2019ulteriore investimento di Niterra Ventures Company apre per noi nuove opportunit\u00e0 per accedere a nuovi mercati, ampliare la nostra piattaforma tecnologica e sviluppare nuovi prodotti<\/em>“, ha dichiarato Ulrike Sailer, CEO di neoplas med<\/strong>. “Non solo facciamo un grande passo avanti, ma garantiamo anche la creazione di nuovi posti di lavoro nel settore high-tech.<\/em>“<\/p>

In Germania, il 75% delle cliniche universitarie e numerosi studi medici e ospedali utilizzano la terapia brevettata al plasma freddo con Argon di neoplas med, che \u00e8 stata impiegata in oltre 500.000 trattamenti a livello globale, comprese le principali cliniche del Medio Oriente. Questo finanziamento sar\u00e0 utilizzato per sviluppare ulteriormente la piattaforma tecnologica e ampliare le operazioni a livello internazionale, con un focus particolare su Stati Uniti, Europa e Medio Oriente.<\/p>

“Niterra Ventures Company sta creando nuove opportunit\u00e0 di business nei settori medicale, cleantech, energetico e IoT per migliorare la qualit\u00e0 della vita attraverso tecnologie all\u2019avanguardia”, <\/em>ha affermato Dirk Schapeler<\/strong>, Presidente di Niterra Ventures Company<\/strong>. “Abbiamo collaborato strettamente con neoplas med negli ultimi anni e siamo entusiasti dell\u2019impatto del kINPen con plasma freddo all\u2019argon sui pazienti. Pertanto, il nostro investimento di follow-on \u00e8 stato un passo naturale<\/em>.”<\/p>

Nell\u2019ambito del suo impegno nel settore medicale, Niterra Ventures Company sta investendo in tecnologie per la rilevazione e valutazione di patologie cardiologiche, oncologiche, neurologiche e ipertensive.<\/p>

“Siamo orgogliosi di supportare neoplas med nel suo ambizioso percorso di crescita, facilitando il raggiungimento di nuovi traguardi e successi continui. La tecnologia al plasma freddo di neoplas med rappresenta un progresso significativo nel settore Healthcare, offrendo soluzioni innovative che migliorano l’efficacia dei trattamenti e la cura dei pazienti in diverse discipline mediche<\/em>“, ha dichiarato il Dr. Ralf Nowak<\/strong><\/a>,<\/strong> Partner di Livingstone<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Livingstone ha svolto il ruolo di advisor finanziario esclusivo per neoplas med GmbH, dopo il successo dei round di finanziamento del 2022 e 2023<\/p>\n","protected":false},"featured_media":2275,"template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"client-type":[],"region":[],"sector":[],"service":[],"transaction-type":[],"class_list":["post-11259","transaction","type-transaction","status-publish","has-post-thumbnail","hentry"],"acf":{"team_members":[1479,1462],"date":"20241125","client_type":49,"type":[1119],"region":[393,387],"services":[450],"sectors":[740,749],"related_transactions":"","related_testimonials":[52374,52375,52376],"contacts":""},"yoast_head":"\nNiterra Ventures Company investe $18m in neoplas med GmbH - Livingstone Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Niterra Ventures Company investe $18m in neoplas med GmbH - Livingstone Partners\" \/>\n<meta property=\"og:description\" content=\"Livingstone ha svolto il ruolo di advisor finanziario esclusivo per neoplas med GmbH, dopo il successo dei round di finanziamento del 2022 e 2023\" \/>\n<meta property=\"og:url\" content=\"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/\" \/>\n<meta property=\"og:site_name\" content=\"Livingstone Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-25T13:00:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\",\"name\":\"Niterra Ventures Company investe $18m in neoplas med GmbH - Livingstone Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"datePublished\":\"2024-11-25T04:00:00+00:00\",\"dateModified\":\"2026-06-25T13:00:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#primaryimage\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/65c7c708.png\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Homepage\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transactions\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/transaction\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Niterra Ventures Company investe $18m in neoplas med GmbH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/\",\"name\":\"Livingstone Partners\",\"description\":\"Deals Done Right.\",\"publisher\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/#organization\",\"name\":\"Livingstone Partners\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"caption\":\"Livingstone Partners\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Niterra Ventures Company investe $18m in neoplas med GmbH - Livingstone Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","og_locale":"it_IT","og_type":"article","og_title":"Niterra Ventures Company investe $18m in neoplas med GmbH - Livingstone Partners","og_description":"Livingstone ha svolto il ruolo di advisor finanziario esclusivo per neoplas med GmbH, dopo il successo dei round di finanziamento del 2022 e 2023","og_url":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","og_site_name":"Livingstone Partners","article_modified_time":"2026-06-25T13:00:45+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","url":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/","name":"Niterra Ventures Company investe $18m in neoplas med GmbH - Livingstone Partners","isPartOf":{"@id":"https:\/\/livingstonepartners.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage"},"image":{"@id":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage"},"thumbnailUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","datePublished":"2024-11-25T04:00:00+00:00","dateModified":"2026-06-25T13:00:45+00:00","breadcrumb":{"@id":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#primaryimage","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/65c7c708.png","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/livingstonepartners.com\/it\/transaction\/niterra-ventures-company-invests-18m-additional-funding-in-neoplas-med-gmbh\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/livingstonepartners.com\/it\/"},{"@type":"ListItem","position":2,"name":"Transactions","item":"https:\/\/livingstonepartners.com\/it\/transaction\/"},{"@type":"ListItem","position":3,"name":"Niterra Ventures Company investe $18m in neoplas med GmbH"}]},{"@type":"WebSite","@id":"https:\/\/livingstonepartners.com\/it\/#website","url":"https:\/\/livingstonepartners.com\/it\/","name":"Livingstone Partners","description":"Deals Done Right.","publisher":{"@id":"https:\/\/livingstonepartners.com\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/livingstonepartners.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/livingstonepartners.com\/it\/#organization","name":"Livingstone Partners","url":"https:\/\/livingstonepartners.com\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/livingstonepartners.com\/it\/#\/schema\/logo\/image\/","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","caption":"Livingstone Partners"},"image":{"@id":"https:\/\/livingstonepartners.com\/it\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/transaction\/11259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/transaction"}],"about":[{"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/types\/transaction"}],"version-history":[{"count":1,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/transaction\/11259\/revisions"}],"predecessor-version":[{"id":68593,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/transaction\/11259\/revisions\/68593"}],"acf:post":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/testimonial\/52376"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/testimonial\/52375"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/testimonial\/52374"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/team-member\/1462"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/team-member\/1479"}],"acf:term":[{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/sector\/749"},{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/sector\/740"},{"embeddable":true,"taxonomy":"service","href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/service\/450"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/region\/387"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/region\/393"},{"embeddable":true,"taxonomy":"transaction-type","href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/transaction-type\/1119"},{"embeddable":true,"taxonomy":"client-type","href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/client-type\/49"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/media\/2275"}],"wp:attachment":[{"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/media?parent=11259"}],"wp:term":[{"taxonomy":"client-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/client-type?post=11259"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/region?post=11259"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/sector?post=11259"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/service?post=11259"},{"taxonomy":"transaction-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/it\/wp-json\/wp\/v2\/transaction-type?post=11259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}